Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial of the National Cancer Institute
Authors:
- 1 November 1994
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 152 (5 Part 2) , 1905-1909
Abstract
Screening for prostate cancer and subsequent treatment is of unknown benefit but carries known treatment related morbidity and mortality risks. The recent enthusiasm for screening in the United States contrasts sharply with the more cautious attitudes of the European and Canadian medical communities. Current data from screening series without randomization and controls are inadequate to determine screening benefit. The prostate, lung, colorectal and ovarian cancer (randomized, controlled) screening trial of the National Cancer Institute, to include 74,000 men (and 74,000 women) 60 to 74 years old, has a design power of 90% to determine a 20% reduction of prostate cancer mortality from a baseline and 3 subsequent annual screens using prostate specific antigen and digital rectal examination. Randomization of participants into this trial began on November 16, 1993. Ten screening centers nationwide, a coordinating center, a laboratory and a biorepository are participating under contract.Keywords
This publication has 26 references indexed in Scilit:
- Prostate Cancer Screening: What We Know and What We Need To KnowAnnals of Internal Medicine, 1993
- Advances in Diagnostic Imaging and Overestimations of Disease Prevalence and the Benefits of TherapyNew England Journal of Medicine, 1993
- The Next Era for Prostate Cancer Controlled Clinical TrialsJAMA, 1993
- The relationship of prostate‐specific antigen to digital rectal examination and transrectal ultrasonography: Findings of the American cancer society national prostate cancer detection projectCancer, 1992
- Case-control study of screening for prostatic cancer by digital rectal examinationsThe Lancet, 1991
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991
- Lack of benefit from semi‐annual screening for cancer of the lung: Follow‐up report of a randomized controlled trial on a population of high‐risk males in czechoslovakiaInternational Journal of Cancer, 1990
- NATURAL HISTORY OF LOCALISED PROSTATIC CANCERThe Lancet, 1989
- Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen.Radiology, 1989
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987